IL21 and neoplasm: Similarly, no statistical difference was observed in the IL-21 serum levels between patients with benign breast lesions and those diagnosed with invasive cancer, considering both the grade of tumour malignancy (p = 0.573) and the biological type of the tumour (p = 0.759) (Figure 2).